There has been incredible advancement for targeted therapies in hormone-positive BC and HER2-positive BC subtypes, but targeted treatment options for TNBC are lacking and the standard of care includes traditional cytotoxic chemotherapy (Shi et al., 2024). The gene discussed is ERBB2; the disease is breast cancer.